{"id":"W2951817901","doi":"10.1016/s0140-6736(19)30764-0","title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":474,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; Daiichi Sankyo Company; Plexxikon; PharmaMar; Eli Lilly and Company; Ignyta; National Institutes of Health; Istituto Ortopedico Rizzoli di Bologna; Eisai; Celldex Therapeutics; Daiichi-Sankyo; Pfizer; Incyte; Five Prime Therapeutics; EMD Serono; Society of Memorial Sloan Kettering; Karyopharm Therapeutics; Exelixis; Memorial Sloan-Kettering Cancer Center; Amgen; Bristol-Myers Squibb; Foundation for the National Institutes of Health","keywords":"Medicine; Placebo; Clinical endpoint; Evening; Internal medicine; Surgery; Surrogate endpoint; Clinical trial; Randomized controlled trial; Intention-to-treat analysis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001392193,0.002107709,0.003083742,0.0003448266,0.0003850994,0.001295303,0.0009042452,0.00197712,0.01098104],"category_scores_gemma":[0.001439972,0.0006669337,0.002861921,0.0003642491,0.001153883,0.001315742,0.000479651,0.00382613,0.001521706],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009621135,"about_ca_system_score_gemma":0.0007667566,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001263228,"about_ca_topic_score_gemma":0.003330763,"domain_scores_codex":[0.9995899,0.0001872744,0.00002341673,0.00008225302,0.00002474828,0.00009237008],"domain_scores_gemma":[0.9994798,0.0001713492,0.0001188955,0.00003792099,0.00003071841,0.0001612984],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9772617,0.001480734,0.0002544451,0.001362426,0.001384981,0.00006217452,0.00004550985,0.0003803557,0.001663922,0.0002027716,0.001692213,0.01420888],"study_design_scores_gemma":[0.9813312,0.01652347,0.0005424515,0.00005479789,0.0004250777,0.00003097011,0.00001871303,0.0001247683,0.00008399046,0.0001859045,0.0006681007,0.00001045318],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9423156,0.03318956,0.001683993,0.00346206,0.003325577,0.004949732,0.003638617,0.0003614711,0.007073236],"genre_scores_gemma":[0.9628934,0.01231495,0.001840046,0.003520774,0.0009665187,0.004527054,0.002266028,0.00005823224,0.01161304],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01098104,"threshold_uncertainty_score":0.0367353,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03192777351594508,"score_gpt":0.3229573369635507,"score_spread":0.2910295634476056,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}